Phase 3 Readout

ALKS: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain
Start: 2026-09-01
End: 2026-09-01

September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2026
Company: Alkermes plc. (ALKS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain

September 1, 2026

ALKS overview →

Company: Alkermes plc. (ALKS)
Indication: Schizophrenia; Bipolar I Disorder